Several drugs entered the U.S. market in 2019, some of which could generate at least $1 billion in annual sales by 2024, according to market research firm EvaluatePharma.
The research firm recently published its Pharma, Biotech & Medtech Half-Year Review that analyzes industry mergers and acquisitions, clinical trials and FDA drug approvals. As part of its report, it ranked the biggest drug approvals to date.
The five biggest drug approvals and their projected 2024 sales:
1. Skyrizi (AbbVie) treats psoriasis — $3.20 billion
2. Vyndaqel (Pfizer) treats heart disease caused by transthyretin mediated amyloidosis — $2.11 billion
3. Zolgensma (Novartis) treats spinal muscular atrophy — $1.57 billion
4. Mayzent (Novartis) treats relapsing multiple sclerosis — $1.31 billion
5. Balversa (Johnson & Johnson) treats advanced or metastatic bladder cancer — $1.15 billion
Access the full report here.